MetaCap

Foghorn Therapeutics Inc. Company Profile

NASDAQ: FHTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.72-0.06 (-3.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Foghorn Therapeutics at a glance

Foghorn Therapeutics Inc. (NASDAQ: FHTX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Watertown, MA. Foghorn Therapeutics is led by Mr. Adrian H. B. Gottschalk and employs about 106 people. The company's shares have traded publicly since 2020.

At a market capitalization of $103.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001822462, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Foghorn Therapeutics do?

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Foghorn Therapeutics Inc.
Ticker
NASDAQ: FHTX
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Adrian H. B. Gottschalk
Employees
106
Headquarters
99 Coolidge Avenue, Watertown, MA, United States
Phone
617 586 3100
IPO year
2020
Market cap
$103.14M
SEC CIK
0001822462
Latest annual report
10-K · Mar 11, 2026

Companies similar to Foghorn Therapeutics

FHTX peer companies
CompanyPrice% ChgMarket capCompare
GNLXGenelux Corporation2.17-4.82%$103.36Mvs FHTX
ORGOOrganogenesis Holdings Inc. Class A0.7716-2.23%$100.16Mvs FHTX
NERVMinerva Neurosciences Inc2.00-5.66%$99.67Mvs FHTX
AKBAAkebia Therapeutics Inc.0.3855-8.71%$107.04Mvs FHTX
CNTNCanton Strategic Holdings Inc.1.21-1.63%$98.78Mvs FHTX
UNCYUnicycive Therapeutics Inc.3.35-5.10%$97.77Mvs FHTX
BGMBGM Group Ltd. Class A8.130.00%$108.57Mvs FHTX
SPRBSpruce Biosciences Inc.38.00-6.15%$109.21Mvs FHTX

Related